Larimar Therapeutics Inc (LRMR)
Featured in
Small-Cap Stocks
Larimar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for rare diseases through its cell-penetrating peptide platform. Its lead candidate, CTI-1601, is being evaluated in a Phase 2 open-label extension study for Friedreich’s ataxia, a rare, progressive, and fatal disease. The company is headquartered in Bala Cynwyd, Pennsylvania, and its common stock trades on the NASDAQ under the ticker LRMR.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LRMR
|
$4.49
|
15.5% Upside
|
Fair
|
$14.40
|
270.2% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-2.4x
|
2.6x
|
—
|
399.8 M
|
209.4 M
|
0.9%
|
57.4%
|
-0.2
|
—
|
79.1%
|
